Engineering Organ-on-a-chip Systems to Model Viral Infections
Overview
Authors
Affiliations
Infectious diseases remain a public healthcare concern worldwide. Amidst the pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 infection, increasing resources have been diverted to investigate therapeutics targeting the COVID-19 spike glycoprotein and to develop various classes of vaccines. Most of the current investigations employ two-dimensional (2D) cell culture and animal models. However, 2D culture negates the multicellular interactions and three-dimensional (3D) microenvironment, and animal models cannot mimic human physiology because of interspecies differences. On the other hand, organ-on-a-chip (OoC) devices introduce a game-changer to model viral infections in human tissues, facilitating high-throughput screening of antiviral therapeutics. In this context, this review provides an overview of theOoC-based modeling of viral infection, highlighting the strengths and challenges for the future.
Du S, Wang Z, Zhu H, Tang Z, Li Q J Transl Med. 2024; 22(1):992.
PMID: 39488714 PMC: 11531701. DOI: 10.1186/s12967-024-05808-1.
Chao Z, Selivanovitch E, Kallitsis K, Lu Z, Pachaury A, Owens R Nat Commun. 2024; 15(1):5606.
PMID: 38961055 PMC: 11222515. DOI: 10.1038/s41467-024-49415-6.
Vasculature-on-a-chip technologies as platforms for advanced studies of bacterial infections.
Gaudreau L, Stewart E Biomicrofluidics. 2024; 18(2):021503.
PMID: 38560344 PMC: 10977040. DOI: 10.1063/5.0179281.
The use of single-cell RNA-seq to study heterogeneity at varying levels of virus-host interactions.
Swaminath S, Russell A PLoS Pathog. 2024; 20(1):e1011898.
PMID: 38236826 PMC: 10796064. DOI: 10.1371/journal.ppat.1011898.
Challenges in development of vaccines directed toward antimicrobial resistant bacterial species.
Brazzoli M, Piccioli D, Marchetti F Hum Vaccin Immunother. 2023; 19(2):2228669.
PMID: 37449650 PMC: 10351463. DOI: 10.1080/21645515.2023.2228669.